INSTRUCTIONS FOR MEDICAL USE
Trade name of the drug: Alsexoline
Active substance (INN): choline alfoscerate
Pharmaceutical form: solution for injection
1 ampoule contains:
Active ingredient: choline alphoscerate 1000 mg/4 ml (in choline alphoscerate hydrate form – 1222.34 mg).
Excipients: Water for injection
Description: colorless or light yellow transparent solution.
Pharmacotherapeutic group: Nootropic medicine.
ATX CODE: N07AX02
Cholinomimetic of central action with predominant effect on CNS. The drug contains 40.5% metabolically protected choline. Choline alphoscerate is split into choline and alphoscerate in the body under the influence of brain enzymes, which are biotransformed to glycerophosphate. Choline is involved in the synthesis of acetylcholine, improving the transmission of nerve impulses, and glycerophosphate is a precursor of phosphatidylcholine of neuronal membranes, resulting in improved membrane elasticity and receptor function.
The drug improves cerebral blood flow, enhances metabolic processes in the brain, activates brain reticular formation structures and restores consciousness after traumatic brain injury. It has preventive and corrective effect on factors of involutional psychoorganic syndrome, such as changes in phospholipid composition of neuronal membranes and decrease in cholinergic activity.
The drug penetrates easily through the blood-brain barrier, and accumulates mainly in the brain (45% of concentration in plasma), as well as in liver and lungs. Excretion is mainly via the lungs in the form of carbon dioxide (85%), the remainder being excreted by the kidneys and the intestine.
Indications for use
- Acute period of craniocerebral injury with predominantly trunk lesions (including in case of impaired consciousness and coma);
- Cerebral circulation disorders of ischemic type (acute and recovery period) and hemorrhagic type (recovery period);
- degenerative and involutionary psychoorganic syndromes and consequences of cerebrovascular insufficiency, such as primary and secondary disorders of mnemastic functions, characterized by memory disorders, confusion, disorientation, decreased motivation, initiative and ability to concentrate; changes in the emotional and behavioral sphere: emotional lability, increased irritability, reduced interest; senile pseudomelancholia;
- multi-infarct dementia.
Administration and dosages
The drug is intended for intramuscular and intravenous administration. In acute conditions, a daily dose of 1 g is administered by injection or intravenously – from 1 g to 3 g per day.
When administered intravenously, 4 ml of the drug are diluted in 50 ml of physiological solution; infusion rate is 60-80 drops/min. The duration of treatment is usually 10 days, but if necessary the treatment can be continued until positive dynamics appear.
Nausea (result of dopaminergic stimulation), allergic reactions. Usually, the drug is well tolerated, even with long-term use.
- Hypersensitivity to the drug components;
- pregnancy and lactation.
Drug interactions with other drugs have not been described.
Usage during pregnancy and lactation
The drug is contraindicated for use in pregnancy. Breast-feeding should be discontinued during the treatment.
Administration in pediatrics
No experience in application in children.
Effect on the ability to drive vehicles and mechanisms
The drug does not affect the ability to drive vehicles and to perform potentially dangerous activities.
In case of overdose, nausea, restlessness and insomnia are registered, which pass after reduction of the dose or discontinuation of the treatment. Therapy is symptomatic.
Form of production
Solution for injection of 1000 mg/4ml №5, №10 (ampules).
Store in a dry place, protected from light, at a temperature not exceeding 25oC. Keep out of the reach of children!
2 years. Do not use after the expiration date.
Conditions for dispensing from pharmacies
Released by doctor’s prescription